Coloplast A/S
CSE:COLO B

Watchlist Manager
Coloplast A/S Logo
Coloplast A/S
CSE:COLO B
Watchlist
Price: 891.6 DKK 2.11% Market Closed
Market Cap: 200.6B DKK
Have any thoughts about
Coloplast A/S?
Write Note

Net Margin
Coloplast A/S

18.7%
Current
21%
Average
2.2%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
18.7%
=
Net Income
5.1B
/
Revenue
27B

Net Margin Across Competitors

Country DK
Market Cap 200.9B DKK
Net Margin
19%
Country JP
Market Cap 6.8T JPY
Net Margin
24%
Country CH
Market Cap 37.9B CHF
Net Margin
12%
Country US
Market Cap 16.9B USD
Net Margin
11%
Country KR
Market Cap 9.9T KRW
Net Margin
-358%
Country CA
Market Cap 6.9B USD
Net Margin
-8%
Country CN
Market Cap 48.6B CNY
Net Margin
42%
Country US
Market Cap 6.3B USD
Net Margin
29%
Country US
Market Cap 6.1B USD
Net Margin
9%
Country UK
Market Cap 4.8B GBP
Net Margin
7%
Country CH
Market Cap 4.9B CHF
Net Margin
12%
No Stocks Found

Coloplast A/S
Glance View

Market Cap
200.9B DKK
Industry
Health Care

Coloplast A/S is a leading global healthcare company headquartered in Denmark, dedicated to the development of innovative medical devices and solutions for individuals with intimate healthcare needs. Founded in 1954, the company has a strong heritage built on empathy and understanding of patient challenges, which drives its continuous commitment to enhancing the quality of life for people with chronic conditions. Coloplast operates in three primary business areas: ostomy care, urology, and continence care, crafting products that empower individuals to manage their health effectively. With a presence in over 40 countries and products sold in more than 100 markets, Coloplast not only boasts a robust portfolio but also demonstrates significant global reach, setting itself apart in a competitive healthcare landscape. For investors, Coloplast presents an attractive opportunity characterized by its steady revenue growth and focus on innovation. The company has implemented a patient-centric approach, which not only fosters brand loyalty but also supports resilience in market fluctuations. With a solid track record of investing in research and development, Coloplast continually enhances its product offerings, ensuring that it remains a trusted partner for patients and healthcare providers alike. As societal trends shift towards personalized and home-based care, Coloplast's strategic initiatives aim to capitalize on these changes, making it well-positioned for sustainable growth in the long term. This strong foundation, marked by operational excellence and a commitment to corporate social responsibility, underscores Coloplast's potential to deliver both solid financial returns and positive societal impact.

COLO B Intrinsic Value
877.42 DKK
Overvaluation 2%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
18.7%
=
Net Income
5.1B
/
Revenue
27B
What is the Net Margin of Coloplast A/S?

Based on Coloplast A/S's most recent financial statements, the company has Net Margin of 18.7%.